Myomo (MYO) Investor Day 2025 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2025 summary
9 Jul, 2026Strategic vision and growth targets
Aims to reach $100 million in annual revenue by 2028, driven by direct billing, O&P channel, and international expansion, with a targeted 32% CAGR.
Direct billing remains the largest revenue contributor, accounting for 79% of Q1 revenue, while O&P and international channels are targeted for significant growth, with O&P expected to contribute 20% by 2028.
International business, primarily in Germany, is expected to reach $15 million by 2028, with 96% of 2024 international revenue from Germany and robust reimbursement.
U.S. O&P channel relaunch targets $20 million in revenue by 2028, focusing on certifying 200 clinicians and expanding partnerships.
Manufacturing capacity is being expanded and insourced to support up to 250 units per month and reduce costs.
Financial outlook and performance
Revenue projected to grow from $32.4 million in 2024 to $100 million in 2028, with gross margin targeted at 70–72% and EBITDA margin of 15–20% by 2028.
Cash flow break-even expected at $17–18 million in quarterly revenue.
Q1 2025 revenue mix: 79% direct billing, 13% O&P, 5% international, 3% VA.
Operating expenses in Q1 2025 mainly payroll and advertising; 26% of COGS is material.
Current cash position and credit facilities are expected to support growth plans, with preference for non-dilutive financing if needed.
Operational improvements and efficiency initiatives
Centralized telehealth screenings and intake operations have improved lead conversion and patient throughput, with scalable processes and increased call volume.
Manufacturing process now leverages remote shape capture, 3D scanning, additive manufacturing, automation, and in-house production for custom devices, reducing lead times and costs.
Lean manufacturing and insourcing of key subassemblies are targeted to deliver 200 basis points of gross margin improvement and 15% savings in key assemblies by end of 2026.
Companion app development will eliminate the need for bundled laptops, further reducing COGS and improving user experience.
Advertising spend has increased, with cost per lead improving and no signs of market saturation.
Latest events from Myomo
- Revenue rose 26% to $40.9M, with 2026 guidance at $43–$46M and recurring sources up to 42%.MYO
Q4 20258 Jul 2026 - Q2 2024 revenue rose 77% to $7.52M, with breakeven targeted for Q4 2024.MYO
Q2 20248 Jul 2026 - Recurring patient sources and expanded payer contracts drive growth toward $100M revenue goal.MYO
IAccess Alpha Virtual Best Ideas Summer Investment Conference 202624 Jun 2026 - Proprietary wearable robotics address a vast unmet need, driving growth toward $100M+ revenue.MYO
Investor presentation23 Jun 2026 - Recurring revenue growth, payer expansion, and clinical validation drive path to profitability.MYO
Sidoti Micro-Cap Virtual Conference21 May 2026 - Wearable robotics drive growth with expanding reimbursement and recurring revenue focus.MYO
Investor presentation20 May 2026 - Recurring revenue and expanded payer coverage fuel growth and improved financial outlook.MYO
A.G.P.'s Annual Virtual Healthcare Conference20 May 2026 - Strong market position, expanding reimbursement, and recurring revenue drive robust growth.MYO
Corporate presentation14 May 2026 - Key votes include director elections, stock plan amendments, and increasing authorized shares.MYO
Proxy filing14 May 2026